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Views on Biotechnology
GEORGEB.RATHMANN

George B. Rathmann is President and Chief Executive Officer of Amgen Inc.

Introduction
Biotechnology is a most remarkable technology. I will
present examples of the biotechnology revolution in widely
diverse areas, including evidence that biotechnology is
remaking the way the world discovers and develops pharmaceuticals and proof that the United States leads the world in
this field. Then, I'll address the issues that have caused some
to say that we should proceed slowly, cautiously, or possibly
not at all. I'll comment on the questions of whether biotech·
nology is safe, wise, and moral and look at both the national
and international perspectives.
This exciting story began in the 50s, when Watson and Crick
said that the greatest impact of their elucidation of the double
helical structure of DNA would be a rapidly growing under·
standing of all life processes. They correctly assessed the
power of DNA and the importance ofbeing able to understand
its structure and manipulate DNA in the laboratory. How
important is DNA to each of us? It turns out that these long
molecules, which represent the blueprints of life are present
in every living cell and the amount in each human being, if
stretched end-to-end, would reach to the sun and back about
150 times. So there is a lot of DNA. An A.mgen scientific
advisory board member once stated that the elegance of DNA
is that each cell contains sufficient information to be equivalent to about five encyclopedias. I accept that as a better
definition of DNA. It surely is the most elegant matter in the
universe.
Manipulating DNA permits us to use the mechanisms of
living cells to make products. It might seem fairly limiting to
only make things that are produced by living cells. But the
extraordinary diversity of life makes it possible to make such
simple molecules as alcohols and esters, acids and amino
acids and then, through metabolic pathways, to make complicated enzymes, vitamins, proteins, and, of course, also to
make DNA itself. So living cells have a great diversity, and the
capabiliry to harness DNA has ushered in the biotechnology
revolution.
Where are the products of biotechnology produced? Not
always, but very frequently in bacteria called E. coli. In the case
of the product interferon, it is produced by the bacterium in
such large quantities that the interferon is sequestered into
little inclusion bodies, thereby helping partially purify the
protein that we want to produce. The production of such a
prodigious quantity of protein literally disables the bacteri urn
to the point where it can no longer reproduce. As a result, we
not only have to be able to insert the human interferon gene
into the E. coli, we must also be able to turn the gene on at will.
The bacteria must be allowed to multiply first.
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This decade began with the announcement in]anuary 1
that Charles Weissman was successfully producing the
wonder drug interferon in a bacterium (1). Interferon is o~
today, after seven years, beginning to live up to the grea~
expectations of that time. However, the true significance of
this announcement was that it stimulated the formation
many new companies that have helped establish the United
States' leadership position. And, of course, in addition , there
was an explosion of optimism about biotechnology.

Progress in Biotechnology to Date
Bioprocessing
One of the early promising potentials of biotech appeared
to be in biomass conversion, to address the serious ene r~
problems faced by the United States in the early 1980s when
fuel prices rose. The thought of supplying simple chemicals
by this new technology was very attractive, but the changes in
oil prices from earlier projections made it uneconomical to try
to make ethanol and other fuels through biotech. Such ·work.
heavily subsidized, is still being done, and certainly will be
important some time in the next century as the availability of
fossil fuels diminishes.
The production of more complicated molecules via bioprocessing continues to offer exciting possibilities. An example of such bioprocessing is the production of indigo dye ~
bacterial cells. This capability was discovered accidentally
when a scientist transferring a biochemical pathway from one
bacteria into another noticed that his cells were turning blue.
The two pathways had interacted to produce indigo, the dye
used for blue jeans. (Indigo has been produced by synthetic
organic chemicals for the past 100 years and was first isolated
from plants more than 2,000 years ago.)
The exciting thing about bioprocessing is that it opens u
the prospect of room temperature production of chemicals.
not the cheapest ones, not the simple alcohols and acids, b
more complicated chemicals that can be produced at room
temperature without toxic catalysts, without toxic fumes, and
without side reactions because biochemical processes can be
highly specific. There is great potential for the production of a
number of other molecules including vitamin C, other vitamins and enzymes. The first wave in the chemical field will be
more complicated molecules than were originally emisioned, but very important products with significant environmental impact.
Agriculture
In the area of agriculture, a number of companies haYe
shown that modified bacteria can improve the conversion of
jo urnal of the Minnesota Academy of Science

nitrogen into the nitrates necessary for plant growth. When
corn and other food crops can benefit from these advances,
the reduction in the use of nitrate fertilizers that will be
possible will have a profound environmental impact. In addition, plants have been genetically altered to resist insects or to
have natural resistance to viruses and other pathogens. The
impact of these developments is certainly going to be impressive, but the impact on the environment may be even more
beneficial.
In summary, within the past six years genes have been
introduced into plants to provide herbicide, insect, and pathogen resistance. The expression of the introduced genes can
be controlled to produce the desired gene products. These
genes are capable of being passed from generation to
generation.
Animal Production and Health
In the areas of animal production and health, milk production has been increased safely in large numbers of animals,
and improved meat quality is now possible. Recombinant
vaccines have also been introduced for animals, and much
progress has been made in general disease control.
For example, the administration of the hormone bovine
somatotropin yields a 15-20% improvement in milk production for only a slight increase in feed. That is, the feed efficiency conversion to milk has been improved. Detection
systems for determining how much administered somatotropin is in the milk show that the amount is essentially the
same as is found in milk naturally; bovine somatotropin is a
natural animal hormone that already exists in the cow.
In the case of pigs, the administration of porcine somatotropin produces a much leaner meat, a much healthier food,
with again more efficient conversion from feed to meat. It is
estimated that 50 million pigs will receive this product when it
is approved.
This work has led people to speculate that soon we will
have animals of weird shapes, designed to serve man and that
we will forget about our responsibility to living things. However, I don't foresee a lot of chimeric animals. But, we should
see the possibility of single cell proteins as a major source of
protein for the world. Some big companies have bet on this
already. Protein is produced with almost economic efficiency
today in large containers that don't have any animals and these
proteins don't even require sunlight. It's disease free, high
quality protein. You can adjust the amino acid ratios to make
sure the protein is perfect. However, it is not a food to which
we are accustomed and it probably will take a long time to get
accustomed to it. This type of food will happen before' we
have strange animals running around in the world; it is a safe
and efficient way to meet humankind's nutritional needs.
Diagnostics
There has been great progress in diagnostics in the last six
years. While monoclonal antibodies are not strictly speaking a
product of recombinant DNA, they are certainly a product of
advanced biotechnology. These very specific immunosystems
provide specificity down to submolecular levels. Hybridization probes, which essentially use the binding action of DNA
(exactly the same binding that holds the double helix
together), have sensitivities down to 10-Js M. The long-range
potential here is much earlier detection of disease so we can
treat it when it is still treatable. The detection of diseases in the
pre-natal stage or genetic screening may also be possible.
Lastly, of course, the discovery of oncogenes and their link to
cancer has given us new insights into that incredibly complex
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process and new cancer diagnostics are underway. Diagnostics are moving relatively rapidly now.
Pharmaceuticals
The major progress that has been most exciting to the world
in the past several years has been in the pharmaceutical arena.
Eight products are now marketed. All the targeted human
proteins originally projected have been cloned, expressed,
and produced at some level, including some very complex
human proteins such as Factor VIII used to treat hemophilia.
There are high expression (production levels) available so
these materials can be produced practically, alleviating early
concerns about whether enough product could be made. It
turns out that for some of these materials one or two pounds
will treat the world for a whole year.
Vaccines of a brand new type have been developed. They
do not contain any of the pathogenic organism's DNA and
cannot replicate. A problem of some conventional vaccines is
sudden reversion and infection by the vaccine itself-no
longer a risk with the new vaccines based on recombinant
DNA. Here a little bit of the coat protein becomes the stimulus
for the body's immune system and no pathogen is introduced
at all. Magic bullets have been produced in which targeted
antibodies carry toxins and destroy pathogenic cells. Major
progress has been made in the past six years.
One of the exciting pharmaceuticals available, erythropoietin, is used to stimulate red blood cell production to combat
certain forms of anemia. It takes about 20 micrograms or less
per day of erythropoietin to restore normal red cell levels for
many people, as compared to a maximum daily dose for
things like Motrin or Tagamet of approximately two grams.
When compared on a weight basis, erythropoietin is 100,000
times more potent, and on a molecular basis, it is 10 million
times more potent. Therefore, we can use 1/10 millionth as
many molecules to produce the therapeutic result. In addition, erythropoietin is a normal human protein which is
exactly like, or very, very close to what is in the body already,
and which has the metabolic pathways of products that
already exist in our bloodstream. We are talking about a
specificity so high that the probability of side effects is absolutely minimal. It is on this basis that it is clear that recombinant DNA affords a new way to produce pharmaceuticals.
A clinical study on erythropoietin, which has gone on now
for a year and a half, indicates that there is a dose dependent
response. Patients that were transfusion dependent can be
taken off transfusions. There is no organ dysfunction, no
antibody formation. The kind of data shown is some of the
finest quantitative human data that has ever been seen with
patient after patient showing responses in hematocrit level
that increase very consistently depending upon the level of
the drug administered. It is almost an idealized curve. Examining the case of a single patient is quite revealing. This patient
had received 14 units of packed red cells in the previous 20
weeks. He was then placed on erythropoietin and given no
more transfusions. The red blood cell level (the hematocrit of
the patient) went up to normal. With transfusions this patient
could not achieve above a 25 hematocrit, which is about 60%
of normal. So we see a dramatic result from, again, microscopic quantities of these natural human proteins (2).
Two other products of biotechnology are tissue plasminogen activator or t- PA and granulocyte colony stimulating factor
( G-CSF). Administration oft-PA can dissolve clots in coronary
arteries interrupting a heart attack
Treatment with G-CSF results in a large increase in white
cells, largely neutrophils. This is exactly what the patient
9

needs in many cases. When cancer treatments destroy the
body's ability to make white cells, the ones that disappear first,
the neutrophils, are the cells that disarm the body's immune
system. By restoring the body's neutrophils, we can bring
patients back to normal. After a round of cancer chemotherapy, if the patient has been treated with G-CSF, studies on a
small but meaningful number of patients indicate that the
neutrophil level never drops below safe levels. The product
looks very promising and it has a number of other applications
in cancer therapy as well. G-CSF is perhaps one year behind
erythropoietin in the extent of clinical studies completed anq,
of course, those will be necessary for final approval.
The exciting aspect of some of these highly directed therapies is the contrast they show to some of the earlier recombinant proteins that had broad responses but a wide spectrum of
side effects. G-CSF and erythropoietin do not have the broad
spectrum of response-each does only one thing, but it does
it very well indeed. It does it without side effects.
Protein Engineering
An exciting new dimension ofbiotechnology that is still largely in the future is protein engineering. The concept here is that
analogs to natural proteins can be made by altering the gene
for that protein. We can take out a few segments of the gene
and replace them with other segments. This is all straightforward molecular biology today. The net effect is that we can
introduce new amino acids at will. The protein generated
might look similar, or it might be that when the new unit is
introduced the whole configuration assumes a very different
shape. Most often if you introduce a new amino acid in a
protein, its characteristics will be destroyed, but if you are very
selective and do it in the right way, you can occasionally
improve the product.
Scientists at Amgen took a somewhat different approach to
protein engineering of alpha interferon. Recognizing that
there are 14 kinds of alpha interferon and that a lot of homology or uniformity exists among the 14 types (see Figure 1),
they concluded that nature was trying to make the concensus
molecule. We averaged all of the 14 structures and produced
that gene and its protein product. (Of course, with genetic
engineering today, that is a very quick job. One can make the
gene and produce the protein in a few weeks.) Our scientists
found their product was, in fact, an active interferon, possibly
five times more active than any of the 14 common ones. This
protein is changed by 14 amino acids from all the others-a
lot of amino acid changes-and yet has improved protein
activity, a most unlikely event. It is obviously a very interesting
product. It is now in advanced testing against viral diseases
and it looks as if it will be a useful antiviral agent.

Results vs. Forecasts
Two years ago at an Industrial Research Institute Conference here in Minnesota, Paine Webber presented projections
for market dates for eleven biologicals (Figure 2). I endorsed
those figures. How well have our forecasts done? At that time
projected marketing for alpha interferon was 1985-87; it went
on the market in 1986 to treat one of the deadliest of cancers,
hairy cell leukemia. From a market standpoint, a small market.
From an importance standpoint, at least for the affected
patients, it is life and death. Beta interferon has not been
introduced yet, although there are some indications for antiviral activity. Also, there is hope that it has anti-cancer properties. It has been approved outside the United States but not
here yet. Probably it will be marketed within those dates. For
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the product erythropoietin, 1990-1992 actually looks conservative. It could well be on the market in the very first part of
that period, but then Food and Drug Administration (FDA)
approval is not easy. The date projected for gamma interferon
(1987-1989) may be a little early. Marketing could be later
than 1989 because of the spectrum of responses the drug has
had-it is very hard to identify where it fits in. In many cases,
the side effects overwhelm the benefits. It is not clear that it
will hit that date. Hepatitis B vaccine went on the market in
1986, earlier than projected. This vaccine is a very important
contribution since 250 million people in the world are
infected with that disease. They will not be helped by the
vaccine, but future infections could be prevented.
Human growth hormone went on the market in 1985, and a
second version of that hormone is going on the market right
now; therefore, two products will be marketed by 1987. For
interleukin-2, there were some very exciting early data (3) ,
some more disappointing data ( 4) , and then a reactivation of
interest in this drug in recent publications in The New Englandjournal of Medicine(5, 6). It certainly looks as if it will be
marketed by 1989, but not by 1987.
Monoclonal antibodies can target toxins, serving as magic
bullets against cancer and magic bullets against infections. It is
difficult to project market dates right now, but development
appears to be on schedule.
Tissue plasminogen activator is definitely scheduled for
this year. It could be the largest biotechnology product for
many years to come.
Tumor necrosis factor is a complex biological response
modifier with many effects other than just simply destroying
tumors, which it does do. Balancing the side effects in human
testing has not been achieved yet. But 1990-1991 is still a
probable marketing date.
I'd like to assert and support the idea that the United States
is leading the world in biotechnology. My view is largely the
result of having traveled around the world and visited with all
the other companies and noted the number of companies
around the world that want Amgen to work with them. We
have many relationships. There are more than 150 relationships between major Japanese companies and small U.S. biotechnology companies. I think that speaks clearly for where
the Japanese think the Americans are. There is no doubt in our
mind that the United States leads in this race. There is also no
doubt that some of the commitments of other countries are
very strong and that gap could close. Certainly it is a good time
to address the balance of trade issues rather than wait until
we're beaten and then try to restore balance by tariffs and
other things. That is important to keep in mind. Other factors
are much more important. The welfare of the people in this
country. The benefits of these products here and around the
world is certainly more important than just deciding we have a
commitment to lead.
With two versions of alpha interferon, as well as insulin,
human growth hormone, and the hepatitis B vaccine on the
market and 30 more products in the development pipeline,
the United States is well ahead in product development.
Indeed each of these productss was introduced into clinical
studies by U.S. firms.

Concerns about Biotechnology
Now let us consider some of the issues that have been
raised about pursuing biotechnolgy, addressing the federal
issues first. Arthur D. Little, a leading management and technology consulting firm, has suggested that there are some
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Figure 1. Comparison of the first 25 amino acids of the 14 naturally occurring forms of interferon. The bottom row is the consensus
sequence generated by AMGen.

serious issues with respect to university and industry relationships, questioning whether we have perturbed the university's
role (7). Actually, this concern was highlighted in 1981 by
Robert Sinsheimer, in an address at the University of California, Santa Cruz, who said, ''This spectacle of faculty seeking to
exploit their research as private entrepreneurs is a scene
fraught with conflicts of interest, destructive of collegiality,
and erosive of the credibility of the university as a source of
disinterested expertise" (8). Manywere extremely concerned
about this and we should be concerned and alert at all times
about the change of the role of the university, which is so vital
to our society. Our experience has been that although many
leading academic people have affiliated themselves with biotech companies, we have never tried to control any of their
publications. We don't review their publications and we don't
fund programs dedicated to our interests. We have issued
some grants, not many however, because of the fear that it
might look as though we are trying to buy their research for us.
I haven't noted any diminution in their dedication to their
students or the principles of the promotion of science in this
country.
Commercialization of biotechnology, of course, is the flip
side of this. If we are going to promote it, how can we do it
well? How can we do it safely? There is also the issue of risks.
Are there risks? There must always be some. Let's make sure
we're not glossing over them. Let's avoid secrecy at all costs.
Let's respect the intellect of the American public and its ability
to understand. Let's not decide what people don't know won't
hurt them. Let's make sure they do understand these risks.
A number of recommendations for action concerning biotechnology policy have been suggested both by A.D. Little and
others (7). U.S. leadership developed in the first place when
Volume 53, Number 1, 1987/88

federal support of research was coupled with the.free enterprise of commercialization of biotechnology in small companies. Support of research should never be eliminated. The
National Science Foundation (NSF) is going to double its
budget in the next five years, but some biological research has
not been growing as rapidly, or even been supported adequately, in the past couple of years. Supporting development
sounds great. Let's do that too, but I am concerned that federal
support of development may reduce the amount of research
supported. Moreover, while research and development tax
breaks sound great, a small company like ours didn't make
money for four years. It really isn't a lot of help not to pay taxes
when company losses mean no taxes are owed. While it is
great for some companies, it doesn't really stimulate the
growth of small companies, which I think is a very important
goal.
Expedite patent action. There is a lot that could be said
about the patent system. A lot of people don't understand it
who should understand it. First, everybody associates the
patent system with secrecy, while in fact, it has the opposite
effect. You can keep a secret or you can patent it. When you
patent it, you are going to file an application that represents
the best embodiment of what you have. Our patents teach you
exactly how to make our products. Within 18 months of the
date we file those patent applications, they are published in
full overseas and around the world. They are picked up by
every country and by every other company. The unfortunate
thing is that we are providing the information in exchange for
patents, which are delayed for years and years because of the
backlog in the Patent Office. I think the United States is
disadvantaged in this regard. Creative companies are disadvantaged because they are providing the information and it is
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PROJECTED MARKET DATES FOR 11 BIOLOGICALS
Product

Market Date

Alpha Interferon

1985-1987

Company
Blogen/Scherlng-Piough
Genentech/Hoffmann-La Roche
Amgen (Concensus alpha)

Beta Interferon

1987-1989

Cetus/Shell Oil
Blogen/Scherlng-Piough
Chiron/Lucky Ltd .

Erythropoietin

1990-92

• Amgen/Kirln
Genetics Institute

Gamma Interferon

1987-1989

Blogen
Genentech/Boehringer /Daiichi
Amgen
Chlron/Lucky Ltd.

Source: Paine Webber

PROJECTED MARKET DATES FOR 11 BIOLOGICALS
Product
Hepatitis B Vaccine

Company

Market Date
1987-1988

Merck/Chlron
Blogen/Green Cross & Wellcome
Amgen

Human Growth Hormone 1985-1986

Genentech/Kabi

lnterleukln 2

lmmunex/Hoffmann-La Roche

1987-1989

Blogen
Amgen
Cetus
Chlron
Monoclonal Antibody

1989-1991

Anticancer Agents
Source: Paine Webber

Cetus
Hybrltech
Xoma

Figure 2. Projected market dates for 11 biologicals.
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PROJECTED MARKET DATES FOR 11 BIOLOGICALS
Product
Monoclonal Antibody

Market Date
1989-1991

Anti-lnfectives

Company
Centocor
Genetic Systems/Cutter
Cetus

Tissue Plasminogen

1986-1988

Activator

Genentech/Boehringer /Mitsublshi
Biogen/ SmithKIIne
Collaborative Research/Sandoz (KPA)
Genetics lnstltute/Wellcome
Integrated Genetics/Toyobo
Chlron/Hoechst

Tumor Necrosis Factor

1990-1991

Genentech/Fujisawa
Cetus

Source: Paine Webber

Blogen/ Sun tory /BASF

Figure 2. Projected market dates for 11 biologicals.

too long before the corresponding patent rights are awarded.
Many people worry about whether it is right to patent things
that are used to treat human beings. The motivation to create
these products is that you are going to be able to market them
under circumstances where not everybody is equal. It wasn't
equal when you discovered them; why should you be equal in
the marketplace. That is the basis of the patent system, which
has stood the test of time for a couple of hundred years and is a
fine system for encouraging creation and innovations. However, problems occur when it takes too long to get the protection that the disclosures justify.
People are interested also in expediting the regulatory
process. There are always some fears when you say that-fears
that we will have all sorts of disasters. However, when the
regulatory process is so comprehensive that when you submit
your documents to the FDA it may take a year to read them,
you know there is something wrong with the process. The
patients who are waiting for that drug could never comprehend taking two years to read the information that is going to
make possible what they already know they want.
Figure 3 summarizes the roles of various federal agencies in
biotech development and regulations. The regulatory process
and whether the government is adequately involved is illustrated here in more than enough detail, indicating just how
many parts of the government are involved in supporting or
investigating, regulating, controlling, or agitating about
biotechnology.
Probably the most controversial column on the chart indicates the Department of Defense's ( DoD) interaction with
Volume 53, Number 1, 1987/ 88

biotech companies. Most of us have have a clear policy from
the beginning. We have no secrets. We registered ourselves as
a genetic engineering company in a community in California
and we said if that is a concern to people, let's explain it to
them. Let's not hide behind a different name. We've had no
secrets. The DoD talked to us on one occasion. The ground
rules they laid out was that we do not discuss biochemical or
biological warfare, offensive or defensive. That was not going
to come up. We had the discussion. We talked about things
like erythropoietin and other materials. That is the only discussion our company has ever had. Some other companies, I
am sure, have also had discussions. The government claims
that it is not conducting offensive weapons research. We
accept that. We certainly haven't. They are not doing any
testing with us and I don't know of anybody with whom they
are doing any. I think it has been of concern because secrecy is
a deadly thing. When you don't hear about it, you don't know
whether you're hearing everything or if something is being
withheld. It is an issue.
However, the issue I was trying to highlight here is the
incredible involvement of the government already. Efforts to
try to simplify this usually scare us into thinking that we're
probably going to end up with something more complicated.
Largely, the system is working. I think it is well controlled. I
think we're over-controlled to some degree and I think it's too
slow, but I don't think we're badly in need of some overlay of
additional and additional layers.
Hidden behind the question of how should the United
States maintain its leadership in biotech, is an additional
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FEDERAL AGENCY ACTIVITIES IN BIOTECHNOLOGY
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Figure 3. Activities of various federal agencies in the development and regulation of biotechnology (7).

question, should the United States maintain its leadership
position in biotechnology? A survey by Monsanto (Figure 4)
indicates there are some concerns out there (9) . It is very
important that we monitor these concerns, understand them,
and try to have communication. Those surveyed were science
policy leaders, environmental leaders, and religious leaders.
Their most serious concern was the risk of creating undesirable organisms.
The surveyors also asked if the respondents believed that
the benefits of biotechnology outweigh the risks. In fact, the
science policy leaders feel so, the environmental leaders feel
so with a little more ambivalence, and the religious leaders
have major concerns. On the negative side, 27% of our religious leaders feel the risks outweigh the benefits. These are
very important issues that should be addressed. Certainly if
you feel the risks do outweigh the benefits, you shouldn't be
trying to proceed and to maintain a leadership position in this
field. We have some educating to do.
There are also others with great concerns. Eugene P. Odum
says that enthusiasm for biotech should not lead us to treat all
organisms merely as commodities for short-term gain (10).
The long·term risk that he fears is undoubtedly ecological.
What he seems to underestimate is the fact that many biotech
products will reduce environmental stress and be used to
detect and clean up some ofthe toxins we are already trying to
eliminate.
Anthony Robbins, staff member on the Committee on
Energy and Commerce, U.S. House of Representatives, says
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everything is going to go toward drain cleaners and cosmetics
( 11). My response to that is a list of vaccines that are in
development for schistosomiasis, malaria, and for AIDS. There
are more than a billion patients suffering from these diseases.
Our hepatitis B vaccine has been tested in China where 1.8
million babies a year, two a minute, are being infected by
hepatitis directly from their mothers. The vaccine works. It
prevents that process. Biotechnology has made great progress
and it is clear that Robbins is underestimating the application
of this technology to do good.
Jeremy Rifkin, founder of the Foundation on Economic
Trends and critic of genetic engineering, said, "Doesn't it
make sense that we forestall biotechnology experiments until
we've had a deep thorough national/international debate?"
(12). He seems to think that will take a finite amount of time.
We're concerned that the debate might well go on and
although it might be a very important activity, it must go on in
parallel with development if we wish to address the concerns
of people who see biotechnology as having the best solution
for their problems. Disease, nutrition, congenital defects,
environment, aging, energy-they are all there to be dealt
with and I don't think we can wait for the resolution of the
total national/international debate.

Conclusion
In summary, biotechnology is solving problems with
health , agriculture, and specialty chemicals. The United States

Journal of the Minnesota Academy of Science

RISK OF MOST CONCERN IS CREATION
OF UNDESIRABLE ORGANISMS
% Respondents expressing risk concerns

90 r-----------------------------------------~
!::':':':':':::1 Science
leaders
80 t - - - - - - ~ Environmental leaders
70 t - - - - - - - - r :
~-----t====r Religious leaders - - - i
60 t--------t::::::::

50 t - - - - - - - - 1
40

t------[

30

t------[

20
10

0
Ecological
concerns

Creation of
undesirable
organisms

Possible
negative
effects on
humans

Ethical
Issues

Use as a
weapon
In warfare

~-------------~
GENE ENGINEERING BENEFITS ARE
SEEN TO OUTWEIGH RISKS
% Respondents to survey

80

r-------------------------------------------~

IE!J Science policy leaders

70

60

Environmental leaders - - - - - - - - t : :':: t - - - - - - - - i
L...liiii.._

Religious leaders -----------J.::::,::;:::::::::t------t

50
40
30

20

t-------t====t---~=

Risks
greater
than
benefits

Risks and
benefits
about even

Benefits
greater
than risks

~-------------~
Figure 4. National survey of leaders in the fields of science policy, environmental issues, and religion on risks related to biotechnology. The
survey was conducted by the Public Opinion Laboratory at Northern Illinois University and was sponsored by Monsanto (9).
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leads in this development and really it is up to us to make sure
that we get a broad enough understanding to maintain the
support for this technology, to move it ahead with responsibility.
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Knowledge is power. Never has that been truer than in
today's information age, with the exponential increase in
human knowledge, with our ever more powerful computing
devices, and with our extraordinary means of communication.
"Give me a place to stand and I will move the earth," said
Archimedes. Today we know that the place to stand is at the
console of a supercomputer.
The other side ofthe coin, and there are always two sides, is
to be found in Ecclesiastes; "He that increaseth knowledge,
increaseth sorrow." The author of Ecclesiastes was not simply
being morose or jaundiced. He knew that with increased
knowledge inevitably comes increased responsibility, for
good or for evil; together with the increased burden of decision; the wider potential for error; and the need for new
ethical guidelines to define the boundaries of action in the
new domain, wrested from the realm of innocence and ignorance.
Today we are at the verge of a most extraordinary advance in
human knowledge, in the domain of the life sciences. We are
about to achieve no less than a complete knowledge and
understanding of the nature of life and the plan of evolutionand thereby of ourselves-as a part of life, a product of evolution.
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The science of biology, in its continuing analysis of the
processes oflife, has penetrated to life's innermost secret-to
the genes, to DNA, to the master programs that define the
nature of each living cell and each living organism.
The genetic programs are carried on the chromosomes in
the structure of very long DNA molecules. The DNA molecules
are the well-known double helixes composed of a ladder of
nucleotide pairs. There are four kinds of pairs and their
sequence conveys the hereditary information. A gene is a tract
of several hundred or several thousand such pairs and is
located in a particular region on a particular chromosome.
We have already determined the complete genetic structure, the DNA sequence, of a few very simple organisms (up to
170,000 nucleotide pairs), and we now have the capacity and
are setting out to determine the complete genetic structure of
higher organisms and specifically, of man. A project is now
being launched to sequence the entire human genome, some
3 billion nucleotide pairs of DNA. It can surely be done. It is
only a matter of time and efficient approach (1).
This knowledge would permit a complete enumeration of
the genetic ingredients of man. We estimate there are 100300,000 genes in Homo sapiens. These will now be defined
and enumerated.
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